10-K: Pulmatrix Pivots to Cullgen Merger, Halts Drug Development

Pulmatrix is shifting its strategic focus to a merger with Cullgen Inc., pausing all internal drug development while seeking to monetize its existing iSPERSE-based assets.

Summary

• Pulmatrix, a biopharmaceutical company, has focused on developing inhaled therapeutic products using its patented iSPERSE technology for migraine and respiratory diseases.
• On November 13, 2024, Pulmatrix entered into a Merger Agreement with Cullgen Inc., which was approved by Pulmatrix stockholders on June 16, 2025, but is still awaiting approval from the China Securities Regulatory Commission (CSRC).
• The End Date for certain termination options in the Merger Agreement was mutually extended by 60 days from August 13, 2025, to October 12, 2025.
• A mutual waiver agreement was entered into on December 17, 2025, waiving compliance with Section 5.4 of the Merger Agreement, which imposed restrictions during the Pre-Closing Period.
• The company is currently exploring opportunities to monetize its iSPERSE technology and existing clinical assets (PUR3100 for migraine, PUR1800 for AECOPD, and PUR1900 for ABPA) and has paused their development.
• Future operations are highly dependent on the success of the Merger; if unsuccessful, the board may decide to pursue a dissolution and liquidation of the company.
• Pulmatrix reported a net loss of $5.2 million for the fiscal year ended December 31, 2025, an improvement from a $9.6 million net loss in 2024.
• The accumulated deficit as of December 31, 2025, was $302.3 million.
• Cash and cash equivalents stood at $4.1 million as of December 31, 2025.
• Research and development expenses significantly decreased to less than $0.1 million in 2025 from $7.2 million in 2024, primarily due to the MannKind Transaction and the winding down of the PUR1900 program.
• General and administrative expenses decreased to $5.1 million in 2025 from $7.8 million in 2024.
• No revenues were recognized for the year ended December 31, 2025, compared to $7.8 million in 2024, primarily due to the completion of PUR1900 Phase 2b clinical trial wind-down activities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly uncertain period for Pulmatrix, with a strategic pivot towards a merger that is not yet finalized and a complete pause on its core drug development activities. While the merger offers a potential path forward, the significant dilution for existing shareholders, the dependence on external regulatory approval, and the explicit mention of potential dissolution and liquidation if the merger fails, indicate a high-risk, low-certainty outlook for the current entity.

Positives

• Net loss decreased to $5.2 million in 2025 from $9.6 million in 2024.
• PUR3100 Phase 1 study demonstrated rapid systemic exposure (Tmax of 5 minutes) and improved tolerability with fewer gastrointestinal side effects (21% nausea vs. 86% for IV DHE, 0% vomiting vs. 29% for IV DHE) compared to intravenous DHE.
• The FDA accepted the IND application for PUR3100 and issued a 'study may proceed' letter for a Phase 2 study in September 2023.
• PUR1800 Phase 1b study showed it was safe and well-tolerated with low and consistent systemic exposure, and chronic toxicology studies support its potential for chronic dosing, possibly expanding indications to steroid-resistant asthma, COPD, or idiopathic pulmonary fibrosis.
• Cipla, Pulmatrix's partner, has continued clinical development of PUR1900 outside the United States, with India's Central Drug Standard Control Organization (CDSCO) approving progression to Phase 3 trials.
• Pulmatrix will receive 2% royalties on any potential future net sales of PUR1900 by Cipla outside the United States.
• The iSPERSE patent portfolio includes approximately 149 granted patents (18 US) with expiration dates from 2026 to 2043.
• The in-licensed kinase inhibitor portfolio includes approximately 284 granted patents (33 US) with expiration dates from 2029 to 2035.

Negatives

• The company has a history of net losses and an accumulated deficit of $302.3 million as of December 31, 2025.
• All product candidates (PUR3100, PUR1800, PUR1900) are currently on hold for development while monetization opportunities are explored.
• Future operations are highly dependent on the success of the Merger with Cullgen, with no assurances that it will be successfully consummated.
• If the Merger is unsuccessful, the board may decide to pursue a dissolution and liquidation of the company.
• No revenues were recognized for the year ended December 31, 2025, a decrease of $7.8 million from 2024.
• The issuance of shares to Cullgen stockholders in the Merger will substantially dilute the voting power of current Pulmatrix stockholders, who are expected to own approximately 3.6145% of the combined company on a fully-diluted basis.
• The company will need to raise additional capital to meet future business requirements, which may be costly or difficult to obtain and could further dilute stockholders' ownership interests.
• The Merger is expected to result in a limitation on the combined company's ability to utilize its net operating loss carryforwards.
• The company is substantially dependent on its remaining two full-time employees, key contractors, and consultants to facilitate the consummation of the Merger.
• The proposed reverse stock split may not increase the combined company's common stock price over the long term, may decrease liquidity, and could lead to a decrease in overall market capitalization.

Risks

• There is no assurance when or if the Merger with Cullgen will be completed, including the failure to obtain approval from the China Securities Regulatory Commission (CSRC).
• Any delay in completing the Merger may substantially reduce the potential benefits expected from the transaction.
• The issuance of shares of common stock to Cullgen stockholders in the Merger will substantially dilute the voting power of current Pulmatrix stockholders.
• The issuance, or expected issuance, of common stock in connection with the Merger could decrease the market price of Pulmatrix common stock.
• The intended benefits of the Merger may not be realized, including potential diversions of management attention and unforeseen integration difficulties.
• The expected disposal of historical assets and operations in connection with the Merger will make Pulmatrix a shell company, subjecting it to more stringent reporting requirements, offering limitations, and resale restrictions.
• Directors and officers of Pulmatrix and Cullgen may have interests in the Merger that are different from, or in addition to, those of stockholders generally.
• If the Merger is completed, Cullgen executive officers and appointees to the Combined Company board of directors will have the ability to significantly influence management and business affairs.
• Failure to complete the Merger could negatively affect the value of Pulmatrix common stock and the future business and financial results of both companies, potentially leading to delisting from Nasdaq or dissolution and liquidation.
• The Merger is expected to result in a limitation on the Combined Company's ability to utilize its net operating loss carryforwards.
• Pulmatrix has a history of net losses and may experience future losses, with an accumulated deficit of $302.3 million as of December 31, 2025.
• The company will need to raise additional capital to fund its operations, and such capital raising may be costly or difficult to obtain and could dilute stockholders' ownership interests.
• All product candidates are still under development, and there can be no assurance of successful commercialization of any products.
• Drug development is a long, expensive, and inherently uncertain process with a high risk of failure at every stage.
• Reliance on third parties to conduct clinical trials, manufacture materials, and supply active pharmaceutical ingredients (APIs) poses risks of non-performance or delays.
• Supply chain and shipping disruptions may result in delays, increased costs, and lost sales.
• The company may not be successful in negotiating an appropriate price in a future sale or assignment of rights related to its current drug candidates.
• Intense competition in the biopharmaceutical industry, with competitors having substantially greater resources.
• Cybersecurity risks could adversely affect the business, financial condition, and results of operations.
• Product candidates must undergo rigorous nonclinical and clinical testing and obtain regulatory approvals, which could be costly, time-consuming, and subject to unanticipated delays.
• Limited experience in filing and pursuing applications necessary to gain regulatory approvals.
• Ongoing regulatory review and compliance requirements could lead to withdrawal of products or sanctions.
• Risk of employee misconduct or other improper activities, including noncompliance with regulatory standards and insider trading.
• Failure to comply with federal or state fraud and abuse laws may adversely affect the business.
• Legislative or regulatory reform of the U.S. healthcare system may adversely affect the business.
• Inability to adequately protect or enforce intellectual property rights could lead to loss of valuable rights and market share.
• Potential for patent-related litigation or proceedings that could be costly and uncertain in outcome.
• The price of Pulmatrix common stock is subject to fluctuation and has been and may continue to be volatile.
• Financial reporting obligations of being a public company are expensive and time-consuming.
• Risk of securities class action litigation.
• Failure to satisfy Nasdaq listing requirements could result in delisting.
• Future issuance of additional equity securities could result in dilution to existing investors.
• Anti-takeover provisions under Delaware corporate law may make it difficult for stockholders to replace or remove the board or deter third parties from acquiring the company.

Future Outlook

The company's future operations are highly dependent on the successful consummation of the merger with Cullgen Inc. If the merger is completed, Cullgen's business will continue as the combined company. Pulmatrix is actively seeking opportunities to monetize its iSPERSE technology and existing clinical assets. However, if the merger is unsuccessful, the Pulmatrix board of directors may decide to pursue a dissolution and liquidation of the company. Continued development of existing product candidates, if it were to occur, would be contingent on securing additional funding and would require significant expenditures and regulatory approvals over several years.

Management Comments

• "We are currently seeking opportunities to monetize iSPERSE and our existing clinical assets."
• "Our future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated."
• "If the strategic review process is unsuccessful, and if the Merger is not consummated, the Pulmatrix board of directors may decide to pursue a dissolution and liquidation of the Company."
• "We believe the PUR3100 formulation of DHE may differentiate from approved DHE products or those known to be in development."
• "If effectiveness is demonstrated, PUR3100 may offer the convenience of being self-administered with a pharmacokinetic profile that may potentially provide rapid onset of action."
• "We believe that this indicates potential for chronic dosing of PUR1800, enabling us to explore PUR1800 therapy for chronic respiratory diseases such as steroid resistant asthma, COPD, or idiopathic pulmonary fibrosis."
• "We believe that PUR1900 compares favorably to the products discussed above and has the potential to generate substantial value based on treating and preventing pulmonary fungal infections in multiple patient populations."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory processes, and intense competition. Pulmatrix's strategic pivot towards a merger and the monetization of its existing assets is a common strategy for smaller biotech firms facing significant funding challenges and the need to de-risk their pipeline. The focus on inhaled therapies for migraine and respiratory diseases, while innovative, places Pulmatrix in competition with both established pharmaceutical giants and other emerging biotechs developing alternative treatments, including other DHE formulations and novel antifungals. The reliance on a partnership with Cipla for international development of PUR1900 is a typical approach to leverage external resources for market expansion and regulatory navigation in diverse jurisdictions.

Comparison to Industry Standards

• PUR3100's Phase 1 results, demonstrating a rapid Tmax of 5 minutes and improved tolerability (lower nausea, no vomiting) compared to IV DHE, position it favorably against existing DHE treatments like intranasal Migranal and Trudhesa, which have faced poor adoption due to incomplete efficacy and intolerability.
• The development of an orally inhaled DHE formulation by Aspeya, Inc. (a Philip Morris International subsidiary), with Phase 1 results pending for a 2025 trial (NCT07226362), indicates direct competition in this specific delivery method for migraine treatment.
• Satsuma Pharmaceuticals' FDA approval of Atzumi, a nasal powder formulation for acute migraine in 2025, further intensifies the competitive landscape for acute migraine therapies.
• Regeneron Pharmaceuticals' dupilumab, which completed a clinical trial in 2024 for ABPA in asthma, showed significant improvements in lung function and reduced exacerbations, setting a high benchmark for new ABPA treatments like PUR1900.
• Pulmatrix's iSPERSE technology aims to offer superior drug loading and delivery efficiency compared to traditional lactose-blend inhaled dry powder therapies, potentially providing a competitive advantage in the inhaled therapeutics market.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings to which the company or its subsidiaries are a party, nor any threatened or pending litigation known to be contemplated by governmental authorities.
• Received multiple demand letters from purported Pulmatrix stockholders demanding additional information related to the merger, which the company believes are without merit and intends to defend vigorously.

Related Party Transactions

• No transactions nor proposed transactions with related persons outside the normal course of business exceeding the lesser of $120,000 or one percent (1%) of the average of the company's total assets since January 1, 2024.
• Peter Ludlum, Interim CEO and CFO, provides services through a consulting agreement with Danforth Advisors, LLC, receiving cash compensation at an hourly rate ($400/hour as CFO, increased to $700/hour for combined CEO/CFO roles).

Stakeholder Impact

• Shareholders face significant dilution from the merger (expected to own ~3.6% of combined company) and potential stock price volatility. There is a possibility of a special cash dividend, but the amount is uncertain and contingent on net cash. Risk of delisting from Nasdaq or dissolution/liquidation if the merger fails.
• Employees (remaining two full-time administrative staff) are dependent on the merger's success for the company's future. The majority of R&D employees were terminated and hired by MannKind in July 2024.
• Partners, such as Cipla, continue to develop PUR1900 outside the US, with Pulmatrix retaining royalty rights. Future monetization efforts for other assets could lead to new partnerships.
• Creditors face increased risk of insolvency if additional funding is not secured or if the merger fails, potentially impacting the company's ability to meet its obligations.

Next Steps

• Complete the Merger with Cullgen Inc., pending CSRC approval and Nasdaq listing approval.
• Monetize iSPERSE technology and existing clinical assets (PUR3100, PUR1800, PUR1900).
• If the Merger is not consummated, the board may decide to pursue a dissolution and liquidation of the company.
• If development of product candidates resumes (contingent on securing additional funding), pursue further clinical studies for PUR3100 (Phase 2) and PUR1800 (potential Phase 2).
• Cipla, the company's partner, will continue clinical development of PUR1900 outside the United States, with approval to proceed to Phase 3 trials.
• Pulmatrix and Cipla will seek to monetize PUR1900 within the United States for suitable indications.
• Invest in protecting and expanding the intellectual property portfolio and file for additional patents.
• Seek partnerships and license agreements to support product development and commercialization of product candidates.

Key Dates

Recommendation

The company is in a highly precarious position, having paused all internal drug development and staked its future entirely on a merger with Cullgen that is not yet complete and faces significant regulatory uncertainty. The potential for substantial dilution for existing shareholders, coupled with the explicit risk of dissolution and liquidation if the merger fails, creates an extremely high-risk investment scenario. The lack of current revenue-generating activities and the reliance on external funding for any future product development further underscore the speculative nature of the stock. A seasoned investor would likely view this as an opportune time to exit, given the profound uncertainties and the potential for significant capital loss.

Keywords

Biopharmaceutical, Merger, Cullgen, iSPERSE, Drug Development, Migraine, COPD, ABPA, Clinical Trials, SEC Filing, 10-K, Nasdaq, Dilution, Net Operating Loss, Patent, Intellectual Property, Healthcare Regulation, Biotech